ASH 2018 | A big year for CLL: ibrutinib updates from ASH
The ALLIANCE A041202 (NCT01886872) and ECOG-E1912 (NCT02048813) trials were major news in the field of chronic lymphocytic leukemia (CLL) at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA. William Wierda, MD, PhD, of the University of Texas MD Anderson Cancer Center, Houston, TX, discusses these trials, which explore the use of ibrutinib as a monotherapy or in combination regimens for elderly and young patients, respectively. Prof. Wierda reveals the superiority of ibrutinib-based therapies to all other arms, with the enhanced PFS and OS rates providing a promising update to the CLL treatment landscape.
Get great new content delivered to your inboxSign up